In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Start-Up Previews, January 2013

Executive Summary

This Month's Profile Group: Personalized Pain Drug Development features profiles of Adynxx, Afferent Pharmaceuticals, and Katama Pharmaceuticals. Plus these Start-Ups Across Health Care: Cognoptix, Endo Tools Therapeutics, ExThera Medical, and Kite Pharma.

You may also be interested in...



Endo Tools Therapeutics SA

Belgium-based Endo Tools Therapeutics SA aims to enable NOTES procedures for treating gastrointestinal disorders such as type 2 diabetes, morbid obesity, and digestive tract tumors. Its Endomina is a universal, multi-channel triangulation platform for use on any existing endoscope through the natural orifices.

ExThera Medical Corp.

In an effort to dramatically reduce the complications associated with bloodstream infections and their progression to sepsis, ExThera Medical Corp. has developed a whole blood affinity therapy device for use in an extracorporeal circuit. Similar in concept to a filter for a swimming pool, the compact Seraph Microbind Affinity Blood Filter has the unique ability to safely remove a wide range of pathogens and toxins from the blood by employing immobilized heparin.

Cognoptix Inc.

Using the eye as a window to the brain, Cognoptix Inc. believes it can detect Alzheimer’s disease before cognitive symptoms appear by evaluating one of the hallmarks of the disorder. Beta amyloid, the protein in the brain that forms plaque, is also found in the lens of the eye.

Topics

Related Companies

UsernamePublicRestriction

Register

IV003951

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel